Search results
Results From The WOW.Com Content Network
He then became founding president and CEO of Orexigen Therapeutics in 2003. In 2004, he became a director at Amicus Therapeutics, based in Cranbury, New Jersey, and in January 2005, he was named the president and CEO of the company. [17] Amicus works to develop treatments for rare, devastating genetic disorders.
Amicus Therapeutics, Inc. is a public American biopharmaceutical company based in Philadelphia, PA. [3] The company went public in 2007 under the NASDAQ trading symbol FOLD. [ 4 ]
Desnick is the author of more than 590 peer-reviewed articles in scientific journals, 250 book chapters and is the editor of 10 books. He holds 26 US issued and licensed patents [ 7 ] and is included in Castle Connelly's lists of Best Doctors in America and Best Doctors in New York and New York Magazine ’s list of the Best Doctors every year ...
(Reuters) -Amicus Therapeutics' treatment for a rare muscle disorder called Pompe disease was approved by the U.S. health regulator, the drugmaker said on Thursday, ending its years-long efforts ...
Shares of Amicus Therapeutics opened 40% lower than yesterday's close on results from a phase 3 study. Amicus and partner GlaxoSmithKline disclosed after the market close Wednesday that migalastat ...
For premium support please call: 800-290-4726 more ways to reach us
Migalastat, sold under the brand name Galafold, is a medication for the treatment of Fabry disease, a rare genetic disorder.It was developed by Amicus Therapeutics.The US Food and Drug Administration (FDA) granted it orphan drug status in 2004, [5] and the European Commission followed in 2006. [6]
Amicus Therapeutics (FOLD) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.